Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

SBS supports Cervical Cancer Awareness Week

10th Jun 2013 16:12

RNS Number : 7048G
Source BioScience PLC
10 June 2013
 



10 June 2013

 

 

Source BioScience plc

('Source BioScience', the 'Group')

 

Source BioScience supports Cervical Cancer Awareness Week

 

To mark Cervical Cancer Awareness Week, Source BioScience, providers of cervical cancer screening technology, joins the National Health Service Cervical Screening Programme ('NHSCSP') and charities, such as Jo's Cervical Cancer Trust, Michelle Henderson Cervical Cancer Trust and MacMillan Cancer Support, in calling for all eligible women to attend their cervical screening test.

The UK leads the way by having the best organised cervical cancer screening programme in the world and sets the standard for other countries in the early detection and treatment of cervical cancer. However, even with this premier standard of care, 1 in 5 women in the UK do not respond to their cervical screening invitation and there are still over 2,900 women in the UK diagnosed with cervical cancer every year.

It is therefore an important message to raise both public awareness that cervical cancer can be prevented by early screening and detection; and to urge women to attend for potentially life saving screening.

Wilma Anderson, Business Manager at Source BioScience commented, "As a previous employee of the NHS, and with 11 years' experience looking down the microscope at cervical slides, I know this test can pick up small changes in the cells that, if untreated, may progress into cervical disease. All women should accept their invitation for testing when they receive it. It can and does save lives as this disease can be treated if caught early."

Source BioScience has been supplying the BD SurePath™ screening technology to the NHSCSP since 2002 and now provides approximately 50% of all cervical cancer screening kits used by the NHS in England and Wales. Last year, approximately two million samples were analysed using the BD SurePath™ platform. Source BioScience has also been working closely with the NHSCSP to introduce automated imaging of cervical slides using the BD FocalPoint™ technology. This can reduce by up to 25% the number of tests which require manual screening, thereby speeding up the turnaround time for patients to receive their results. To date seven systems have been adopted by five NHS Trusts with further uptake expected during 2013.

Nick Ash, CEO of Source BioScience, added: "There is a major benefit to women in attending their routine cervical screening test and we recognise the excellent work of organisations such as Jo's Cervical Cancer Trust and the NHSCSP in raising awareness of this disease and need for testing. The action and activities of these organisations help to ensure this disease can be caught early and treated, and has significantly reduced the incidence of cervical cancer in the UK."

-Ends-

For further information, please contact:

Source BioScience plcWilma AndersonBusiness Manager, Healthcare

Tel: +44 (0) 781 132 6412

www.sourcebioscience.com

College Hill (PR Agency to Source BioScience)Melanie Toyne-Sewell/Stefanie BacherTel: +44 (0)207 457 2020Mob: +44 (0)7992 693760Email: [email protected]

 

About Source BioScience:

Source BioScience plc (LSE: SBS) is an international diagnostics and genetic analysis business serving the healthcare and research markets. The LifeSciences division provides core laboratory research support from conceptualisation to implementation, calling upon a wide range of cutting-edge technology platforms including an online catalogue of biomolecular tools. The Group is a trusted provider of a complete range of sophisticated microarray, next generation and conventional sequencing services. GLP, GCP and CPA accreditations make the sequencing offerings also very attractive for applications in regulatory studies or clinical settings. Its Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases in addition to complementary products for serology and diagnostic applications. The Group has its headquarters in Nottingham, UK. Further information about Source BioScience can be found at www.sourcebioscience.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAFMMATMBBBBMJ

Related Shares:

SBS.L
FTSE 100 Latest
Value8,275.66
Change0.00